Feasibility of a Partnered Approach to Prevent Diabetes

NCT ID: NCT00302055

Last Updated: 2016-12-01

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

72 participants

Study Classification

INTERVENTIONAL

Study Start Date

2006-03-31

Study Completion Date

2007-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The Diabetes Prevention Program (DPP) demonstrated that an intensive lifestyle intervention resulting in modest weight loss and increased physical activity can delay or prevent the development of type 2 diabetes in those at increase risk for the disease. The lifestyle program used, however, was not designed for delivery on a public health scale. Successful DPP translation will require a sustainable partnership between a health care system and an established community organization committed to community health and experienced in implementing sustainable health and wellness programs. We have been collaborating with local health system and community administrators for over a year to design a 'real-world' clinic-based screening model to identify and refer high-risk patients for a group-based adaptation of the DPP lifestyle intervention in community facilities. We have designed this study to develop preliminary data about the feasibility and yield of clinic-based screening and referral, as well as the effectiveness of the adapted lifestyle intervention. This pilot study seeks to: 1) evaluate the feasibility of a strategy to implement American Diabetes Association (ADA) recommendations for clinic-based diabetes-risk testing and to refer high-risk patients for a community-based lifestyle intervention; 2) compare two strategies to enhance community-based program participation by referred patients; 3) demonstrate the capability of community facilities to schedule and enroll referred clinic patients at high-risk for diabetes and to deliver a modified, group-based DPP lifestyle intervention consistently; and 4) compare levels of weight loss and physical activity achieved by referred clinic patients with pre-diabetes who participate in a free-of-charge, group-based DPP lifestyle intervention at community facilities compared to a free-of-charge, traditional, one-on-one DPP lifestyle intervention at a DPP research site. Addressing these issues now will enable us to evaluate this partnered DPP translation model with a larger, more robust future study that will involve referral by multiple primary care clinics, program delivery at more community sites, and a 3-year follow-up period.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pre-diabetic State Overweight Obesity

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

one-on-one lifestyle

Clinical referral to diabetes prevention lifestyle intervention at School of Medicine campus

Group Type ACTIVE_COMPARATOR

Clinical referral to diabetes prevention lifestyle

Intervention Type BEHAVIORAL

16 one-hour lifestyle program sessions (diet and physical activity skill building and problem solving) delivered about once weekly over 20-24 weeks, followed by monthly lifestyle maintenance sessions

group-based community lifestyle

Clinical referral to group diabetes prevention lifestyle intervention program in community

Group Type EXPERIMENTAL

Clinical referral to group diabetes prevention lifestyle

Intervention Type BEHAVIORAL

16 one-hour lifestyle program sessions (diet and physical activity skill building and problem solving) delivered about once weekly over 20-24 weeks, followed by monthly lifestyle maintenance sessions

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Clinical referral to diabetes prevention lifestyle

16 one-hour lifestyle program sessions (diet and physical activity skill building and problem solving) delivered about once weekly over 20-24 weeks, followed by monthly lifestyle maintenance sessions

Intervention Type BEHAVIORAL

Clinical referral to group diabetes prevention lifestyle

16 one-hour lifestyle program sessions (diet and physical activity skill building and problem solving) delivered about once weekly over 20-24 weeks, followed by monthly lifestyle maintenance sessions

Intervention Type BEHAVIORAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

25 years of age or older Body-mass index of \>= 24 kg/m2

1. or more additional risk factors if age is \<45

\- Parent or sibling with diabetes
* Minority race or ethnicity
* History of gestational diabetes
* Delivery of infant \>= 9 lbs.
* History of high blood pressure
* History of dyslipidemia
* Polycystic Ovarian Syndrome
* History of vascular disease Fasting Capillary Glucose 95 - 125 mg/dl 2-hour Post-challenge Capillary Glucose 140 - 199 mg/dl

Exclusion Criteria

Diseases that could limit lifespan or increase risk with a lifestyle intervention - Cancer diagnosed in the past 5 years

\- Significant Cardiovascular Disease

\- A "Yes" response to any item on the modified Physical Activity Readiness Questionnaire

\- Uncontrolled hypertension: systolic blood pressure \>180 mmHg or diastolic blood pressure \>105 mmHg
* Heart attack, stroke, or transient ischemic attack within 6 months
* Chest pain or unexplained dizziness or fainting with physical exertion
* Chronic obstructive pulmonary disease or asthma needing home oxygen
* Other chronic disease or condition, such as advanced arthritis, that could limit ability to become physically active or limit life span to \<5 years
* Any other known reason for not participating in regular physical activity

Exclusions related to metabolism - Past anti-diabetes medication use, except during gestational diabetes

\- Use of a medications known to produce hyperglycemia

\- Known disease leading to abnormal glucose metabolism

Exclusions for conditions / behaviors likely to affect study conduct

\- Unable or unwilling to provide informed consent
* Unable to communicate with the pertinent clinic staff
* Unable to read written English or Spanish
Minimum Eligible Age

25 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Northwestern University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Ronald Ackermann

Professor

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Ronald T Ackermann, MD, MPH

Role: PRINCIPAL_INVESTIGATOR

Northwestern University Feinberg School of Medicine

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

IU Medical Group Westside Clinic

Indianapolis, Indiana, United States

Site Status

IU Medical Group Banta Road Clinic

Indianapolis, Indiana, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

DK71527 (completed)

Identifier Type: -

Identifier Source: org_study_id